BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 16551861)

  • 1. A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma.
    Uemura H; Fujimoto K; Tanaka M; Yoshikawa M; Hirao Y; Uejima S; Yoshikawa K; Itoh K
    Clin Cancer Res; 2006 Mar; 12(6):1768-75. PubMed ID: 16551861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells.
    Bleumer I; Tiemessen DM; Oosterwijk-Wakka JC; Völler MC; De Weijer K; Mulders PF; Oosterwijk E
    J Immunother; 2007 Jan; 30(1):116-22. PubMed ID: 17198090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients.
    Suekane S; Nishitani M; Noguchi M; Komohara Y; Kokubu T; Naitoh M; Honma S; Yamada A; Itoh K; Matsuoka K; Kanayama H
    Cancer Sci; 2007 Dec; 98(12):1965-8. PubMed ID: 17919310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme.
    Terasaki M; Shibui S; Narita Y; Fujimaki T; Aoki T; Kajiwara K; Sawamura Y; Kurisu K; Mineta T; Yamada A; Itoh K
    J Clin Oncol; 2011 Jan; 29(3):337-44. PubMed ID: 21149665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of erythropoietin receptor-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from HLA-A24(+) patients with renal cell carcinoma.
    Minami T; Minami T; Shimizu N; Yamamoto Y; De Velasco M; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
    Int Immunopharmacol; 2014 May; 20(1):59-65. PubMed ID: 24583149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer.
    Aruga A; Takeshita N; Kotera Y; Okuyama R; Matsushita N; Ohta T; Takeda K; Yamamoto M
    Clin Cancer Res; 2013 Apr; 19(8):2224-31. PubMed ID: 23479678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer.
    Noguchi M; Itoh K; Suekane S; Yao A; Suetsugu N; Katagiri K; Yamada A; Yamana H; Noda S
    Cancer Sci; 2004 Jan; 95(1):77-84. PubMed ID: 14720331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele.
    Sakamoto S; Matsueda S; Takamori S; Toh U; Noguchi M; Yutani S; Yamada A; Shichijo S; Yamada T; Suekane S; Kawano K; Sasada T; Hattori N; Kohno N; Itoh K
    Cancer Sci; 2015 Oct; 106(10):1257-63. PubMed ID: 26212219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24
    Minami T; Matsumura N; Sugimoto K; Shimizu N; De Velasco M; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
    Int Immunopharmacol; 2017 Mar; 44():197-202. PubMed ID: 28110220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Programmed Death Ligand 1-derived Peptides Capable of Inducing Cancer-reactive Cytotoxic T Lymphocytes From HLA-A24+ Patients With Renal Cell Carcinoma.
    Minami T; Minami T; Shimizu N; Yamamoto Y; De Velasco M; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
    J Immunother; 2015 Sep; 38(7):285-91. PubMed ID: 26261892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbon anhydrase IX specific immune responses in patients with metastatic renal cell carcinoma potentially cured by interleukin-2 based immunotherapy.
    Rasmussen S; Donskov F; Pedersen JW; Wandall HH; Buus S; Harndahl M; Braendstrup P; Claesson MH; Pedersen AE
    Immunopharmacol Immunotoxicol; 2013 Aug; 35(4):487-96. PubMed ID: 23802595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer.
    Kono K; Mizukami Y; Daigo Y; Takano A; Masuda K; Yoshida K; Tsunoda T; Kawaguchi Y; Nakamura Y; Fujii H
    Cancer Sci; 2009 Aug; 100(8):1502-9. PubMed ID: 19459850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients.
    Takahashi R; Toh U; Iwakuma N; Takenaka M; Otsuka H; Furukawa M; Fujii T; Seki N; Kawahara A; Kage M; Matsueda S; Akagi Y; Yamada A; Itoh K; Sasada T
    Breast Cancer Res; 2014 Jul; 16(4):R70. PubMed ID: 24992895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma.
    Komohara Y; Harada M; Arima Y; Suekane S; Noguchi M; Yamada A; Itoh K; Matsuoka K
    Int J Oncol; 2006 Dec; 29(6):1555-60. PubMed ID: 17088996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients.
    Takahashi R; Ishibashi Y; Hiraoka K; Matsueda S; Kawano K; Kawahara A; Kage M; Ohshima K; Yamanaka R; Shichijo S; Shirouzu K; Itoh K; Sasada T
    Cancer Sci; 2013 Oct; 104(10):1285-94. PubMed ID: 23829867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients.
    Mine T; Gouhara R; Hida N; Imai N; Azuma K; Rikimaru T; Katagiri K; Nishikori M; Sukehiro A; Nakagawa M; Yamada A; Aizawa H; Shirouzu K; Itoh K; Yamana H
    Cancer Sci; 2003 Jun; 94(6):548-56. PubMed ID: 12824881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
    Motomura Y; Ikuta Y; Kuronuma T; Komori H; Ito M; Tsuchihara M; Tsunoda Y; Shirakawa H; Baba H; Nishimura Y; Kinoshita T; Nakatsura T
    Int J Oncol; 2008 May; 32(5):985-90. PubMed ID: 18425324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant tumor and autoantigen vaccination supports renal cell carcinoma rejection.
    Herbert N; Haferkamp A; Schmitz-Winnenthal HF; Zöller M
    J Immunol; 2010 Jul; 185(2):902-16. PubMed ID: 20548033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.
    Noguchi M; Kobayashi K; Suetsugu N; Tomiyasu K; Suekane S; Yamada A; Itoh K; Noda S
    Prostate; 2003 Sep; 57(1):80-92. PubMed ID: 12886526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers.
    Tsuda N; Mochizuki K; Harada M; Sukehiro A; Kawano K; Yamada A; Ushijima K; Sugiyama T; Nishida T; Yamana H; Itoh K; Kamura T
    J Immunother; 2004; 27(1):60-72. PubMed ID: 14676634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.